SEGMENT INFORMATION

3 Months Ended

Mar. 31, 2013

SEGMENT INFORMATION [Abstract]

SEGMENT INFORMATION

NOTE 4.              SEGMENT INFORMATION

We operate in one business segment: the research, development and commercialization of pharmaceutical products.  Our corporate headquarters in the United States collects product sales, licensing fees, royalties, and sponsored research revenues from our arrangements with external customers and licensees.  Our entire business is managed by a single management team, which reports to the Chief Executive Officer.

Our revenues are currently derived primarily from five licensees for international activities and our domestic sales activities of Altrazeal®.

Revenues per geographic area for the three months ended March 31 are summarized as follows:

Revenues	2013		%			2012		%
Domestic	$	19,787		19	%	$	52,046		87	%
International		82,257		81	%		7,959		13	%
Total	$	102,044		100	%	$	60,005		100	%

A significant portion of our revenues are derived from a few major customers.  Customers with greater than 10% of total sales for the three months ended March 31 are represented on the following table:

Customers	Product	2013			2012
Customer A	Altrazeal®		75	%		*
Customer B	Aphthasol®		---			27	%
Customer C	Altrazeal®		*			16	%
Customer D	Altrazeal®		*			11	%
Total			75	%		54	%
* Sales from this customer were less than 10% of total sales for the period reported.